Platform
Features
NextPhase Therapeutics
Contact
Carlos Paya is a board member of two publicly listed companies (NYSE and NASDAQ). He was President and CEO, Immune Design Corp, until its acquisition by Merck.
This person is not in the org chart
9 members
Ad
Pluristem Therapeutics
Integrated Resources, Inc ( IRI )
Anivive
REGENXBIO
CRISPR Therapeutics